What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence is based on a single phase 2 randomized controlled trial comparing felzartamab to placebo, which shows some efficacy signals such as resolution of antibody-mediated rejection in 82% of patients versus 20% in placebo. However, the lack of active comparator data against standard of care limits the ability to claim superiority, thus justifying a B++ rating.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses, ICERs, or QALY estimates are provided in the reviewed evidence. The absence of economic evaluations results in a C rating, indicating non-cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
There is no evidence of HRQoL data or validated instruments reported in the clinical trials for felzartamab. The absence of any HRQoL measures leads to a C rating, indicating a critical gap in evidence.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The phase 2 trial reported that adverse events were predominantly mild or moderate, with serious adverse events occurring less frequently in the felzartamab group compared to placebo. This favorable safety profile supports an A+ rating.
Was the drug compared against what payers expect? — Comparator Selection
The comparator used in the pivotal trial is placebo, which is appropriate given the lack of approved therapies for AMR. However, this limits the ability to assess comparative effectiveness against standard treatments, leading to a B+ rating.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is somewhat representative of the intended patient population, but the small sample size and lack of subgroup analyses limit generalizability. Thus, a B++ rating is appropriate.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment integrates well into existing care pathways, requiring biopsy-based diagnosis and monitoring, which are standard practices in AMR management. This leads to an A rating.
Are the wider system costs understood? — Resource Use and Cost Implications
While the trial outlines resource use in terms of infusions and monitoring, there is no quantification of costs or implications for broader resource use, resulting in a B rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from a well-designed phase 2 trial, but the small sample size and exploratory nature introduce limitations. Thus, a B++ rating reflects moderate confidence in the evidence quality.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty due to the lack of economic evaluations and broader impact assessments in the evidence reviewed. This leads to a C rating, indicating unacceptable uncertainty.
